---
title: "MFP: Net sales rose 13.2% and orders increased 16% year-over-year, with guidance raised for 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295840612.md"
description: "Completed spin-off and launched as an independent public company, reporting 13.2% net sales growth and a 16% increase in orders year-over-year. Raised full-year 2026 guidance, with strong liquidity and a new $50 million share repurchase program.Original document: Midera Food Processing, Inc. [MFP] SEC 8-K Current Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-13T20:16:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295840612.md)
  - [en](https://longbridge.com/en/news/295840612.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295840612.md)
generator: "portal-rs"
---

# MFP: Net sales rose 13.2% and orders increased 16% year-over-year, with guidance raised for 2026

Completed spin-off and launched as an independent public company, reporting 13.2% net sales growth and a 16% increase in orders year-over-year. Raised full-year 2026 guidance, with strong liquidity and a new $50 million share repurchase program.

Original document: Midera Food Processing, Inc. \[MFP\] SEC 8-K Current Report — Aug. 13 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [MFP.US](https://longbridge.com/en/quote/MFP.US.md)

## Related News & Research

- [Midera Food Processing director Robert A. Nerbonne acquires 10,900 common shares for $491,045.50](https://longbridge.com/en/news/296407364.md)
- [Rapala VMC: Strong H1 sales and profit growth led to upgraded full-year outlook amid ongoing trade risks](https://longbridge.com/en/news/296480810.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)
- [BEWI: Q2 2026 delivered double-digit sales and EBITDA growth, with strong performance across all segments](https://longbridge.com/en/news/296303987.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**